contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lidds-strengthens-the-organization-with-two-new-recruitments

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patented and clinically tested drug delivery technology. The properties of the products form the basis of the LIDDS technology platform for the development of injectable pharmaceutical products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System, and the company is headquartered in Uppsala.

LIDDS

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company has recruited Annette Møldrup as Chief Business Development Officer and Kia Bengtsson as Head of Clinical Development. Both...

<div class="mfn-preamble"><p><strong>UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company has recruited Annette Møldrup as Chief Business Development Officer and Kia Bengtsson as Head of Clinical Development. Both have extensive experience from the pharmaceutical industry and will assume their new roles in the autumn 2022.</strong></p></div><div class="mfn-body"><p>“This is an important step for LIDDS’ future development and I am very happy to welcome Annette and Kia to the company. With Annette’s business development experience we will take an important step towards increasing our ability to negotiate and realize deals and also improve the awareness about LIDDS internationally. Through Kia we will get strong contribution to the clinical development of our portfolio.” says Nina Herne, CEO of LIDDS.</p><p>Annette Møldrup has long experience from the pharmaceutical industry where she has worked within global business development at Novo Nordisk and most recently at Ferring. Annette will be part of the management team. She has a Cand.Scient of Biochemistry and PhD of Molecular and Cellular Biology from University of Copenhagen. Annette assumes her new role on September 1, 2022.</p><p>Kia has 25 years experience from clinical development from among others AstraZeneca, Nanologica, Eurocine Vaccines and Ipsen. She comes most recently from the role as Head of Clinical Development at Vivesto. Kia is a registered nurse from the Karolinska Institute and assumes her new role on October 1, 2022</p></div><div class="mfn-footer mfn-contacts mfn-cb73eb895ad4"><p><strong class="mfn-heading-1">For additional information, please contact</strong></p><hr><p>Nina Herne, CEO<br>Phone: +46 (0)70&nbsp;714 74 57<br>E-mail: <a rel="nofollow noopener" href="mailto:nina.herne@liddspharma.com">nina.herne@liddspharma.com</a><br>&nbsp;<br>Jenni Björnulfson, CFO<br>Phone: +46 (0)70 855 38 05<br>E-mail: <a rel="nofollow noopener" href="mailto:jenni.bjornulfson@liddspharma.com">jenni.bjornulfson@liddspharma.com</a></p><p>LIDDS’ Certified Adviser is Redeye AB<br>Tel: +46 (0)8 121&nbsp;576 90<br>E-mail: certifiedadviser@redeye.se</p></div><div class="mfn-footer mfn-about mfn-dcb9e4cb41ff"><p><strong class="mfn-heading-1">LIDDS in brief:</strong></p><hr><p>LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="nofollow noopener" href="https://storage.mfn.se/95bfb923-1a86-4995-8ae3-c8133da7d175/lidds-strengthens-the-organization-with-two-new-recruitments.pdf" class="mfn-generated mfn-primary">LIDDS strengthens the organization with two new recruitments</a></p></div>